These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36748356)

  • 1. Novel approach to decision making for orphan drugs.
    Decker B; Mlcoch T; Pustovalova A; Dolezal T
    Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
    Vostalová L; Mazelová J; Samek J; Vocelka M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
    Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
    Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
    Iskrov GG; Raycheva RD; Stefanov RS
    Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of moral reasons on orphan drug reimbursement.
    Zimmermann BM; Eichinger J; Baumgartner MR
    Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
    Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
    Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan drugs policies: a suitable case for treatment.
    Drummond M; Towse A
    Eur J Health Econ; 2014 May; 15(4):335-40. PubMed ID: 24435513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing access to orphan medicinal products in Europe.
    Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
    Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R; Bertele' V; Garattini S
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
    Annemans L; Makady A
    Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HTA criteria adopted in different models of public healthcare systems for orphan drugs: A scoping review.
    Felippini A; Biglia LV; Lima TM; Aguiar PM
    Health Policy; 2024 Jun; 144():105080. PubMed ID: 38733643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.